Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe tumor environment to predict drug resistance in stomach cancer

NCT ID NCT07692477

Knowledge-focused Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By mapping immune and blood vessel-related features in the tumor environment, they aim to identify markers that predict treatment response or resistance. The goal is to improve personalized treatment decisions for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict which patients will benefit from chemotherapy plus immunotherapy, potentially improving treatment choices.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (age \>= 18 years) with histologically confirmed, operable, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, candidate to perioperative treatment with FLOT plus durvalumab at the participating IRCCS centers. Patients are enrolled consecutively as they start perioperative treatment in clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the stomach (gastric cancer, GC) or gastroesophageal junction (GEJ) 2. Operable, locally advanced disease (T \>= 2 and/or node-positive) according to AJCC 8th edition staging 3. Candidate for perioperative chemotherapy with FLOT regimen combined with durvalumab, as per clinical practice 4. Age \>= 18 years 5. Provision of written informed consent prior to any study-specific procedure Exclusion Criteria: 1. Presence of another active malignant disease 2. Advanced or metastatic gastric/GEJ cancer not eligible for surgical treatment 3. Inability or unwillingness to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric adenocarcinoma Gastroesophageal junction adenocarcinoma (siewert ii-III)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.